Immunoglobulins clinical trials
Also written TAK-771.
A group of medicines. Immunoglobulins, Intravenous (227 studies) is counted on its own page; this page counts the studies that name Immunoglobulins itself.
How each study uses Immunoglobulins is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Immunoglobulins studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Medicines filed under Immunoglobulins
As reviewed, so not every one. Each counts its studies on its own page, not here.
Studies by the year they started
46 studies that test it; most in 2020 (6)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1992 | 1 |
| 1993 | 1 |
| 1995 | 3 |
| 1996 | 1 |
| 1997 | 1 |
| 1998 | 1 |
| 2004 | 3 |
| 2005 | 3 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 6 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 31
CSL Behring (7) · Takeda (4) · Assistance Publique - Hôpitaux de Paris (3) · University of Aarhus (3) · University Health Network, Toronto (2) · Baxalta now part of Shire (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · National Center for Research Resources (NCRR) (2)
Often tested with
Tested in the same studies.
Immunoglobulin G (4) · Immunoglobulins, Intravenous (3) · Adrenal Cortex Hormones (2) · Aspirin (2) · Solutions (1) · Hyaluronoglucosaminidase (1) · Albumins (1) · Hydroxychloroquine (1)
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Immunoglobulins is the comparator. A study of two new drugs counts under both.
- 1Amoxicillin · Monash University · next primary completion Apr 2027
- 1Clavulanic Acid · Monash University · next primary completion Apr 2027
- 1Ciprofloxacin · Monash University · next primary completion Apr 2027
Studies
Open first, then newest update. How each study uses Immunoglobulins is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 47
- A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingPhase 3Kedrion S.p.A.NCT06752356Written as Immune globulin (human) 10% solution for intravenous administration
- Immunoglobulin Replacement Therapy (IgRT) Versus Antibiotic Prophylaxis (PA) in Patients Treated by CD19-targeted Chimeric Antigen Receptor (CAR)T Cells for a B Cell Acute Lymphoblastic Leukemia or a B Cell LymphomaNot yet recruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07754682Written as Immunoglobulin
- Randomised Evaluation of COVID-19 TherapyRecruitingPhase 3University of OxfordNCT04381936Written as Immunoglobulin
- Study on Glucocorticoid Combined With Gamma Globulin and Ropristine N01 in Treatment of Initial Severe ITPRecruitingPhase 2Wuhan Union Hospital, ChinaNCT06686927Written as corticosteroids combined with immunoglobulin and romiplostim
- Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC)RecruitingPhase 4University of AarhusNCT04589299Written as Immunoglobulin
- Intravenous Immunoglobulin Replacement Therapy for Persistent COVID-19 in Patients With B-cell ImpairmentRecruitingPhase 2Jaehoon KoNCT06159283Written as Immunoglobulins
- Efficacy and Safety of Immunoglobulin Associated With Rituximab Versus Rituximab Alone in Childhood-Onset Steroid-dependent Nephrotic SyndromeCompletedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT03560011Written as immunoglobulin IV
- An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)CompletedPhase 4CSL BehringNCT07076446Written as IgPro
- A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)CompletedPhase 3TakedaNCT05084053Written as TAK-771
- A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) ParticipantsCompletedPhase 3TakedaNCT05513586Written as TAK-771
- Subcutaneous Immunoglobulin for Myasthenia GravisCompletedPhase 2University Health Network, TorontoNCT04728425Written as subcutaneous immunoglobulin (SCIG)
- An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency DiseaseCompletedPhase 3TakedaNCT04842643Written as IGSC 20% infusion
- A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)CompletedPhase 3TakedaNCT05150340Written as TAK-771
- A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)CompletedPhase 3Baxalta now part of ShireNCT04346108Written as Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
- A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)CompletedPhase 3Baxalta now part of ShireNCT02549170Written as IGIV GAMMAGARD LIQUID/KIOVIG
- Convalescent Antibodies Infusion in Critically Ill COVID 19 PatientsTerminatedNot applicableA.O. Ospedale Papa Giovanni XXIIINCT04346589Written as Anti-coronavirus antibodies (immunoglobulins)obtained with DFPP from convalescent patients
- Convalescent Antibodies Infusion in COVID 19 PatientsWithdrawnNot applicablePiero Luigi RuggenentiNCT04418531Written as Anti-coronavirus antibodies (immunoglobulins) obtained with DFPP form convalescent patients
- Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous IgCompletedPhase 2/3Rochester General HospitalNCT03211065Written as 20% subcutaneous immunoglobulin
- Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral ImmunodeficiencyWithdrawnPhase 3Green Cross CorporationNCT03492710Written as Immunoglobulin
- Intravenous Immune Globulin to Treat Hereditary Inclusion Body MyopathyCompletedPhase 1National Human Genome Research Institute (NHGRI)NCT00195637Written as Immune Globulin
See all 47 studies that test Immunoglobulins →
Given beside what is tested · 2 — Immunoglobulins is usual care or a partner of the new treatment
- Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory NeuronopathyRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06373211Written as Immunoglobulins IV (CLAYRIG)
- A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)Status unknownPhase 3National Taiwan University HospitalNCT03200561Written as immunoglobulin
As the comparator · 3 — what is tested is compared with Immunoglobulins
- Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)RecruitingPhase 2University of UlmNCT04881682Written as Immunoglobulins
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or ExtensionRecruitingPhase 2/3Monash UniversityNCT05678621Written as Immunoglobulins
- Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal TransplantationTerminatedPhase 2Brigham and Women's HospitalNCT01895127Written as Immunoglobulin
Codes
What other systems call Immunoglobulins · ClinicalTrials.gg INT007650
- MeSH (NLM) D007136ImmunoglobulinsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D007136 | Immunoglobulins | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.